Auna (NYSE:AUNA – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.
A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Auna in a report on Wednesday. Zacks Research downgraded shares of Auna from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, JPMorgan Chase & Co. dropped their price objective on Auna from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.97.
View Our Latest Research Report on Auna
Auna Price Performance
Auna (NYSE:AUNA – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.14). The firm had revenue of $336.84 million for the quarter, compared to analyst estimates of $320.54 million. Auna had a net margin of 1.53% and a return on equity of 16.25%. Analysts anticipate that Auna will post 0.81 earnings per share for the current fiscal year.
Insider Activity
In related news, President Leon Jesus Zamora acquired 30,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were bought at an average price of $4.39 per share, with a total value of $131,700.00. Following the transaction, the president directly owned 45,914 shares of the company’s stock, valued at $201,562.46. This trade represents a 188.51% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Wilton sold 17,574 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.17, for a total value of $73,283.58. Following the completion of the sale, the director owned 49,974 shares of the company’s stock, valued at approximately $208,391.58. This represents a 26.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have bought 83,454 shares of company stock worth $357,063 in the last quarter.
Institutional Investors Weigh In On Auna
Several hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Auna by 487.7% during the first quarter. Renaissance Technologies LLC now owns 668,457 shares of the company’s stock worth $3,683,000 after purchasing an additional 554,707 shares during the period. Marshall Wace LLP increased its stake in Auna by 391.0% during the 4th quarter. Marshall Wace LLP now owns 162,992 shares of the company’s stock valued at $802,000 after purchasing an additional 129,799 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Auna during the 1st quarter valued at $557,000. Goldman Sachs Group Inc. increased its stake in Auna by 43.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 71,645 shares of the company’s stock valued at $352,000 after purchasing an additional 21,579 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Auna during the first quarter worth $324,000.
About Auna
Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.
The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.
Recommended Stories
- Five stocks we like better than Auna
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Auna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auna and related companies with MarketBeat.com's FREE daily email newsletter.
